Sanara MedTech Inc. (SMTI) Next Earnings Date & Expected ±4% Move

$32.92 +0.11% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Sanara MedTech Inc. (SMTI) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $302.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510057
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C
Cash (9)Whales (9)SEC (14)Macro (11)CEO (14)
Each axis scored 0–20
12M PRICE TARGET CONE-0.5% Base Target
$39 Bull$33 Base$26 Bear
📬 FREE SMTI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SMTI)Realized 20D OHLCV Swing Band: ±4%
NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±4% Swing Band

±$1.32 Expected Swing
$31.60 (-4%)Spot $32.92$34.24 (+4%)
MODEL EARNINGS SETUP GAUGE

SMTI Quantitative Pre-Earnings Setup: 57/100

Trailing EPS: $4.09 • YoY Revenue Growth: 19%

Model Bullish Setup (57/100)Model Risk Weight (43/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$103.1M$37.6M$2.2M92.7%
FY 20242024-12-31$86.7M$9.7M-$229.6K90.6%
FY 20232023-12-31$65.0M$4.3M-$3.2M92%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SMTI)

  • ✓Walkthrough of SMTI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SMTI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +73.35%🛡️ HOLDING TREND SUPPORT
2026-10-30O $32.76H $33.19L $32.66C $32.92VOL 97.2K
RES: $36.29SUP: $31.64SMA50: $34.51SMA200: $25.48
$36.76$31.62$26.47$21.32$16.17RES $36.29SUP $31.64$32.922026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SMTI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
-5.2%/yr Implied 5Y Growth

vs. +19.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SMTI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SMTI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SMTI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SMTI)

Health Care Rank #256 of 1016 ⚔️ ZJYL vs SMTI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SMTI vs. ZJYL, INGN, AVR, AGPU)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sanara MedTech Inc. (SMTI) ranks #256 by composite RQD confidence (57/100, grade D+) and #518 by equity capitalization ($302.4M). Within this direct 5-issuer industry benchmark cohort, SMTI leads on earnings valuation at 8.1x trailing P/E, while SMTI leads on capital efficiency and profitability with 16.3% ROIC and 92.7% gross margin. SMTI currently leads its immediate peer cohort in composite quantitative strength at 57/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SMTI ACTIVE
Sanara MedTech Inc.
D+ 57/100 8.1x 92.7% 16.3% +0.11% $302.4M Benchmark Subject
ZJYL
JIN MEDICAL INTERNATIONAL LTD. (Class A)
D 47/100 — 29.2% — -2.10% $294.2M /zjyl-vs-smti →
INGN
Inogen Inc
E 29/100 8.5x 52.2% -27.0% +0.14% $192.7M /ingn-vs-smti →
AVR
Anteris Technologies Global Corp.
D- 36/100 — 70.3% -35.0% +5.25% $625.9M /avr-vs-smti →
AGPU
Axe Compute Inc.
D- 37/100 — — -35.0% -2.01% $101.7M /agpu-vs-smti →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000714256

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sanara MedTech Inc. (SMTI) reported GAAP revenue of $103.1M (+19.0% vs. FY2024 revenue of $86.7M , and +58.7% cumulative change since FY2023) , GAAP net income of $37.6M, operating cash flow of $6.8M, and free cash flow of $2.2M (+1041.1% YoY). On the balance sheet, SMTI closed FY2025 with $72.9M in total assets against $46.0M in total debt (Altman Z-Score: 3.25, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $103.1M $37.6M $6.8M $2.2M $72.9M $46.0M
FY2024 (FY) 2024-12-31 $86.7M $9.7M -$23.8K -$229.6K $88.1M $30.7M
FY2023 (FY) 2023-12-31 $65.0M $4.3M -$3.2M -$3.2M — —

3. SMTI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SMTI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Sanara MedTech Inc. (NASDAQ: SMTI) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $32.92 (+0.11% 1D, market cap $302.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, SMTI ranks #256 in composite RQD confidence.

How does SMTI compare to ZJYL and INGN in the Health Care sector?

Within the Health Care sector (Industrial Specialties), SMTI carries a Roarable D+ (57/100 RQD), trailing P/E of 8.1x, gross margin of 92.7%, and ROIC of 16.3%. By comparison, ZJYL (JIN MEDICAL INTERNATIONAL LTD. (Class A)) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $294.2M) and INGN (Inogen Inc) posts a E grade (29/100 RQD, P/E 8.5x, ROIC -27.0%, cap $192.7M). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SMTI?

Per SMTI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000714256), Sanara MedTech Inc. generated $103.1M in revenue (+19.0% YoY), $37.6M in net income, and $2.2M in free cash flow against $72.9M in total assets and $46.0M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SMTI trading relative to its 50-day, 200-day, and 52-week technical levels?

SMTI last traded at $32.92 (+0.11% on volume of 35,140 shares), positioning the stock -4.61% below its 50-day simple moving average ($34.51) and +29.20% above its 200-day simple moving average ($25.48). Across its 52-week range of $16.05 to $35.52, SMTI sits at the 86.6% percentile with a 14-day RSI of 27.3 (OVERSOLD (<32)) and an implied next-earnings move of ±4.0% ($31.60 to $34.24).

SMTI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is SMTI's next earnings date?

Based on SEC filing cadence, Sanara MedTech Inc. (SMTI)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is SMTI stock expected to move on earnings?

Volatility modeling currently projects a ±4% event move for SMTI, spanning a range between $31.6 and $34.24.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $213.66 -0.80% AAPL $348.91 +1.48% MSFT $530.14 -0.16% TSLA $403.30 -0.23% PLTR $196.42 -0.20% SOFI $17.61 +2.74% IBIT $43.36 -0.94% GLD $355.78 -1.34%